通过 Continuum+ 平台报告的药品不良反应概况:为期三年的地区跟踪调查结果。

IF 2.2 4区 医学 Q3 PHARMACOLOGY & PHARMACY
Juliette Henry , Audrey Fresse , Mathilde Beurrier , Marie-Lauren Antoine , Pierre Gillet
{"title":"通过 Continuum+ 平台报告的药品不良反应概况:为期三年的地区跟踪调查结果。","authors":"Juliette Henry ,&nbsp;Audrey Fresse ,&nbsp;Mathilde Beurrier ,&nbsp;Marie-Lauren Antoine ,&nbsp;Pierre Gillet","doi":"10.1016/j.therap.2024.04.001","DOIUrl":null,"url":null,"abstract":"<div><div><span>In 2017, the Continuum+ platform was launched to provide a monitoring solution to home-based cancer care patients: AKO@dom monitoring. This platform also offers the follow-up of adverse drug reactions (ADRs) via direct notification to regional centers of </span>pharmacovigilance<span><span> (RCPVs). According to previous studies, the AKO@dom monitoring has successfully maintained treatment at the maximum effective dosage, managing ADRs and patient satisfaction. However, on the pharmacovigilance side, opinions are more divided. Due to the launch of the AKO@dom-PICTO experimentation in December 2021, in which our RCPV takes part, and to provide more data on pharmacovigilance, we decided to conduct a descriptive analysis of cases reported to our RCPV via the Continuum+ platform between 2019 and 2022. During these three years, we analyzed 1070 events, corresponding to 37 patients. Patients were primarily women (74.8%) aged around seventy with breast cancer. The most used drugs were tyrosine kinase inhibitors<span>: palbociclib (29.7%), </span></span>axitinib<span> (16.2%), and cabozantinib (13.2%). Patients had an average of 8 ADRs, including one serious and/or unexpected ADR. Although the Continuum+ platform makes it possible to considerably limit under-reporting in pharmacovigilance, it has shortcomings. The lack of medical elements and context in notifications is a massive problem for analyzing pharmacovigilance reports. Improved access to the platform's medical information for RCPVs and pharmacovigilance training for healthcare professionals would make Continuum+ a helpful tool in pharmacovigilance.</span></span></div></div>","PeriodicalId":23147,"journal":{"name":"Therapie","volume":"79 6","pages":"Pages 692-698"},"PeriodicalIF":2.2000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Profile of adverse drug reactions reported via the Continuum+ platform: Results from three-year regional follow-up\",\"authors\":\"Juliette Henry ,&nbsp;Audrey Fresse ,&nbsp;Mathilde Beurrier ,&nbsp;Marie-Lauren Antoine ,&nbsp;Pierre Gillet\",\"doi\":\"10.1016/j.therap.2024.04.001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div><span>In 2017, the Continuum+ platform was launched to provide a monitoring solution to home-based cancer care patients: AKO@dom monitoring. This platform also offers the follow-up of adverse drug reactions (ADRs) via direct notification to regional centers of </span>pharmacovigilance<span><span> (RCPVs). According to previous studies, the AKO@dom monitoring has successfully maintained treatment at the maximum effective dosage, managing ADRs and patient satisfaction. However, on the pharmacovigilance side, opinions are more divided. Due to the launch of the AKO@dom-PICTO experimentation in December 2021, in which our RCPV takes part, and to provide more data on pharmacovigilance, we decided to conduct a descriptive analysis of cases reported to our RCPV via the Continuum+ platform between 2019 and 2022. During these three years, we analyzed 1070 events, corresponding to 37 patients. Patients were primarily women (74.8%) aged around seventy with breast cancer. The most used drugs were tyrosine kinase inhibitors<span>: palbociclib (29.7%), </span></span>axitinib<span> (16.2%), and cabozantinib (13.2%). Patients had an average of 8 ADRs, including one serious and/or unexpected ADR. Although the Continuum+ platform makes it possible to considerably limit under-reporting in pharmacovigilance, it has shortcomings. The lack of medical elements and context in notifications is a massive problem for analyzing pharmacovigilance reports. Improved access to the platform's medical information for RCPVs and pharmacovigilance training for healthcare professionals would make Continuum+ a helpful tool in pharmacovigilance.</span></span></div></div>\",\"PeriodicalId\":23147,\"journal\":{\"name\":\"Therapie\",\"volume\":\"79 6\",\"pages\":\"Pages 692-698\"},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2024-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Therapie\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0040595724000428\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapie","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0040595724000428","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

2017 年,Continuum+ 平台推出,为居家癌症护理患者提供监测解决方案:AKO@dom 监测。该平台还通过直接通知区域药物警戒中心(RCPV)的方式,提供药物不良反应(ADR)的跟踪服务。根据以往的研究,AKO@dom 监控系统成功地将治疗维持在最大有效剂量,控制了药物不良反应并提高了患者满意度。然而,在药物警戒方面,意见却较为分歧。由于 AKO@dom-PICTO 实验将于 2021 年 12 月启动,我们的 RCPV 也将参与其中,为了提供更多的药物警戒数据,我们决定对 2019 年至 2022 年期间通过 Continuum+ 平台向我们的 RCPV 报告的病例进行描述性分析。在这三年中,我们分析了 1070 起事件,对应 37 名患者。患者主要为女性(74.8%),年龄在七十岁左右,患有乳腺癌。使用最多的药物是酪氨酸激酶抑制剂:帕博西利(29.7%)、阿西替尼(16.2%)和卡博替尼(13.2%)。患者平均出现 8 例 ADR,其中包括 1 例严重和/或意外 ADR。尽管 Continuum+ 平台可以大大减少药物警戒中的漏报现象,但它也有不足之处。通知中缺乏医疗要素和背景信息是分析药物警戒报告的一个大问题。改进 RCPV 对平台医疗信息的访问,并对医疗保健专业人员进行药物警戒培训,将使 Continuum+ 成为药物警戒方面的有用工具。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Profile of adverse drug reactions reported via the Continuum+ platform: Results from three-year regional follow-up
In 2017, the Continuum+ platform was launched to provide a monitoring solution to home-based cancer care patients: AKO@dom monitoring. This platform also offers the follow-up of adverse drug reactions (ADRs) via direct notification to regional centers of pharmacovigilance (RCPVs). According to previous studies, the AKO@dom monitoring has successfully maintained treatment at the maximum effective dosage, managing ADRs and patient satisfaction. However, on the pharmacovigilance side, opinions are more divided. Due to the launch of the AKO@dom-PICTO experimentation in December 2021, in which our RCPV takes part, and to provide more data on pharmacovigilance, we decided to conduct a descriptive analysis of cases reported to our RCPV via the Continuum+ platform between 2019 and 2022. During these three years, we analyzed 1070 events, corresponding to 37 patients. Patients were primarily women (74.8%) aged around seventy with breast cancer. The most used drugs were tyrosine kinase inhibitors: palbociclib (29.7%), axitinib (16.2%), and cabozantinib (13.2%). Patients had an average of 8 ADRs, including one serious and/or unexpected ADR. Although the Continuum+ platform makes it possible to considerably limit under-reporting in pharmacovigilance, it has shortcomings. The lack of medical elements and context in notifications is a massive problem for analyzing pharmacovigilance reports. Improved access to the platform's medical information for RCPVs and pharmacovigilance training for healthcare professionals would make Continuum+ a helpful tool in pharmacovigilance.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Therapie
Therapie 医学-药学
CiteScore
3.50
自引率
7.70%
发文量
132
审稿时长
57 days
期刊介绍: Thérapie is a peer-reviewed journal devoted to Clinical Pharmacology, Therapeutics, Pharmacokinetics, Pharmacovigilance, Addictovigilance, Social Pharmacology, Pharmacoepidemiology, Pharmacoeconomics and Evidence-Based-Medicine. Thérapie publishes in French or in English original articles, general reviews, letters to the editor reporting original findings, correspondence relating to articles or letters published in the Journal, short articles, editorials on up-to-date topics, Pharmacovigilance or Addictovigilance reports that follow the French "guidelines" concerning good practice in pharmacovigilance publications. The journal also publishes thematic issues on topical subject. The journal is indexed in the main international data bases and notably in: Biosis Previews/Biological Abstracts, Embase/Excerpta Medica, Medline/Index Medicus, Science Citation Index.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信